Готові списки джерел за темами / Ulcerative colitise

Добірка наукової літератури з теми "Ulcerative colitise"

Автор: Grafiati
Опубліковано: 7 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Ulcerative colitise".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Статті в журналах з теми "Ulcerative colitise":

1

Costa, Gabrielle Azevêdo, Giovanna Souza Carvalho, Lenzzy Coelho Pereira, Stephanie Gesteira Vilas Boas Sena Costa, and Cristina Aires Brasil. "Epidemiological Profile of Patients with Crohn's Disease and Ulcerative Colitis in the Last 6 Years." Journal of Health Sciences 24, no. 1 (March 22, 2022): 63–66. http://dx.doi.org/10.17921/2447-8938.2022v24n1p63-66.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract Inflammatory bowel diseases, Crohn's Disease and Ulcerative Colitis, are two relevant changes in the intestinal microbiota of individuals who are subject to environmental and genetic changes. With the social development and, mainly, the spread of industrialization, the increase in gastrointestinal diseases was observed on a large scale. Therefore, the study permeated to relate and obtain its results according to ethnicity, sex, phenotypic alterations of PID and gender, which are risk factors for these diseases. To characterize the epidemiological profile of patients with Crohn's Disease and Ulcerative Colitis in Brazil in the last 6 years. This is a time series epidemiological study with the objective of collecting data from patients who were diagnosed with Crohn's Disease and Ulcerative Colitis, in all Brazilian regions from 2014 to 2019. Data will be collected in the System of SUS Hospital Information (SIH/SUS), within a period of 6 years and for the analysis of these data, sociodemographic variables will be used, namely: ethnicity, sex, region, age group and admissions number, being accessed on 09/22/2020. The panorama presented shows high rates of hospitalization in the Southeast and Northeast regions, the diagnosis for the two diseases predominate in the South region, females, ethnicity/white race and age group between 20 and 29 years highlighted. Thus, the intervention of public policies that improve the population's health condition is of paramount importance. Keywords: Hospitalization. Epidemiology. Inflammatory Bowel Diseases. ResumoAs doenças inflamatórias intestinais, Doença de Crohn e a Colite Ulcerativa, são duas alterações pertinentes na microbiota intestinal de indivíduos que estão sujeitos a mudanças do ambiente e genéticas. Com o desenvolvimento social e, principalmente, alastramento da industrialização o aumento das doenças gastrintestinais foi observado em larga escala. Sendo assim, o estudo permeou em relacionar e obter os seus resultados de acordo a etnia, sexo, alterações fenotípicas de IDP e gênero, que são fatores de riscos para essas doenças. O objetivo desse estudo foi caracterizar o perfil epidemiológico de pacientes com doença de Crohn e colite ulcerativa, no Brasil, nos últimos 6 anos. Trata-se de um estudo epidemiológico de serie temporal com o objetivo de coletar dados de pacientes que foram diagnosticados com doença de Crohn e colite ulcerativas, em todas as regiões brasileiras no período de 2014 até 2019. Os dados serão coletados no Sistema de Informações Hospitalares do SUS (SIH/SUS), dentro do período de 6 anos e para a análise desses dados, serão utilizadas as variáveis sociodemográficas, que são: etnia, sexo, região, faixa etária e números de internações, sendo acessado no dia 22/09/2020. O panorama apresentado demostra altas taxas de internação nas regiões sudeste e nordeste, o diagnóstico para as duas doenças predominam na região sul, o sexo feminino, etnia/raça branca e faixa etária entre 20 e 29 anos em destaque. Desta forma, é de suma importância a intervenção de políticas públicas que melhorem a condição de saúde da população. Palavras-chave: Hospitalização. Epidemiologia. Doenças Inflamatórias Intestinais.
2

Tobin, Jacinta M., Bidisa Sinha, Pramila Ramani, Abdul R. H. Saleh, and M. Stephen Murphy. "Upper Gastrointestinal Mucosal Disease in Pediatric Crohn Disease and Ulcerative Colitis: A Blinded, Controlled Study." Journal of Pediatric Gastroenterology and Nutrition 32, no. 4 (April 2001): 443–48. http://dx.doi.org/10.1002/j.1536-4801.2001.tb07295.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
ABSTRACTBackgroundUpper gastrointestinal endoscopic biopsies often show histologic abnormalities in Crohn disease. Consequently, it has been proposed that routine endoscopy could help to distinguish Crohn disease from ulcerative colitis. Surprisingly, however, recent case reports and an uncontrolled study suggested that similar abnormalities may occur in ulcerative colitis. Therefore, a blinded, controlled study was performed.MethodsEsophageal, gastric antral, and duodenal biopsies from children with Crohn disease (n = 28) and ulcerative colitis (n = 14) were compared with those from controls undergoing endoscopy for suspected reflux esophagitis (n = 22). Two pathologists, unaware of patient identity and diagnosis, agreed on a consensus report. Severity of inflammation was scored semiquantitatively. Helicobacter pylori colonization was an exclusion criterion.ResultsInflammation was reported as follows: esophagitis: controls 91%; Crohn disease: 72%; ulcerative colitis: 50%; gastritis: controls: 27%; Crohn disease: 92% (P < 0.001); ulcerative colitis: 69%; duodenitis: controls: 9%; Crohn disease: 33%; ulcerative colitis: 23%. In Crohn disease, granulomas were noted in 40% of patients (P = 0.001). Duodenal cryptitis was noted in 26% of patients with Crohn disease but not ulcerative colitis. In one patient with ulcerative colitis, neutrophilic infiltration of gastric glands was seen. Abnormalities seen in Crohn disease and ulcerative colitis included gastroduodenal ulceration (Crohn disease, 7%; ulcerative colitis, 8%), villus atrophy (Crohn disease, 11%; ulcerative colitis, 15%), and increased intraepithelial lymphocytes (Crohn disease, 15%; ulcerative colitis, 31% [P < 0.05]). None of these abnormalities was noted in the controls.ConclusionAlthough the presence of granulomas can support a diagnosis of Crohn disease, severe inflammation and other abnormalities occur in the proximal gastrointestinal tract in Crohn disease and ulcerative colitis.
3

Garey, Kevin W., Daniel S. Streetman, and Michael C. Rainish. "Azathioprine Hypersensitivity Reaction in a Patient with Ulcerative Colitis." Annals of Pharmacotherapy 32, no. 4 (April 1998): 425–28. http://dx.doi.org/10.1345/aph.17395.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
OBJECTIVE: To describe a case of azathioprine hypersensitivity in a patient with ulcerative colitis. CASE SUMMARY: A 40-year-old white man with ulcerative colitis, treated with chronic mesalamine and occasional steroids, was admitted to the hospital with a 3-day history of fever, nausea, vomiting, and a rash. Fourteen days prior to admission, the patient had been started on azathioprine for ulcerative colitis. Upon admission, azathioprine therapy was temporarily withheld, resulting in resolution of his signs and symptoms. Symptoms returned when azathioprine was restarted. It was decided that these signs and symptoms were most likely caused by azathioprine hypersensitivity, and the agent was discontinued. DISCUSSION: To our knowledge, this is the first reported case of azathioprine hypersensitivity in a patient with ulcerative colitis. The time course and presenting signs and symptoms support the diagnosis of azathioprine hypersensitivity, as does the patient's response to rechallenge. The mechanism of this hypersensitivity reaction is unclear, but may involve the nitroimidazole portion of the azathioprine molecule. CONCLUSIONS: Azathioprine hypersensitivity often presents with signs and symptoms resembling a systemic infection such as fever, leukocytosis, and evidence of end organ dysfunction. The diagnosis of azathioprine hypersensitivity should be considered in patients who have recently either initiated or increased their dosage of azathioprine. OBJETIVO: Reportar un caso de hipersensitividad a azathioprine en un paciente con colitis ulcerativa. RESUMEN DEL CASO: Un hombre de 40 años con colitis ulcerativa tratado cronicamente con mesalamine y ocasionalmente esteroides, fue hospitalizado con un historial de 3 días con fiebre, naúsea, vómitos, e irritación en la piel. Catorce días previo a la admisión, el paciente había comenzado en azathioprine para su colitis ulcerativa. En la admisión, la azathioprine fue temporalmento descontinuada resultando en la resolución de los signos y síntomas. Los síntomas comenzaron cuando se utilizó nuevamente el azathioprine. Se decidió que estos signos y síntomas eran bien parecidos a una hipersensitividad a azathioprine y el medicamento fue descontinuado. DISCUSIÓN: Hasta donde se conoce es el primer caso reportado con hipersensitividad a azathioprine en un paciente con colitis ulcerativa. El tiempo del curso y presentación de los signos y síntomas apoyan el hallazgo así como la respuesta del paciente al ser tratado nuevamente. El mecanismo de esta hipersensitividad no está claro pero podría envolver la porción de nitromidazole de la mólecula de azathioprine. CONCLUSIONES: A menudo la hipersensitividad a azathioprine presenta los signos y síntomas parecidos en una infección sistémica como fiebre, leucosiotosis, y evidencia de disfunción en órganos terminales. El diagnóstico de hipersensitividad a azathioprine debe ser considerado en pacientes que recientemente comenzaron en el medicamento y en casos en que se les aumente la dosis de azathioprine. OBJECTIF: Rapporter un cas d'hypersensibilité à l'azathioprine chez un patient atteint de colite ulcéreuse. RÉSUMÉ DU CAS: Un homme de 40 ans attéint de colite ulcéreuse et traité de façon chronique avec de la mésalamine et occasionnellement avec des corticostéroïdes a été admis à l'hôpital pour fièvre, nausées, vomissements, et rash persistant depuis 3 jours. Quatorze jours avant son admission, un traitement à l'azathioprine avait été débuté pour sa colite ulcéreuse. À l'admission, l'azathioprine a été temporairement cessée, ce qui a permis la résolution des signes et symptômes. Les symptômes sont réapparus lorsque l'azathioprine a été reprise. Les signes et symptômes présentes par le patient étant compatibles avec une réaction d'hypersensibilité à l'azathioprine, il fut décidé de cesser définitivement l'azathioprine. DISCUSSION: Selon les auteurs, il s'agirait du premier cas d'hypersensibilité à l'azathioprine rapporté chez un patient atteint de colite ulcéreuse. l'évolution de la réaction dans le temps, les signes et symptômes de même que la réapparition des symptômes lors de la réadministration du médicament tendent à incriminer l'azathioprine. Le mécanisme de cette réaction d'hypersensibilité n'est pas clairement défini mais pourrait impliquer la portion nitroimidazole de la molécule d'azathioprine. CONCLUSIONS: L'hypersensibilité à l'azathioprine se manifeste fréquemment par des signes et symptômes ressemblant à une infection systémique tels que fièvre, leucocytose, et évidence de dysfonction d'un organe. Le diagnostic d'hypersensibilité à l'azathioprine devrait être considéré chez les patients qui reçoivent depuis peu de l'azathioprine ou chez qui la dose d'azathioprine a été augmentée.
4

Silvia Pop, Corina, Roxana Maria Nemes, and George Pariza. "Surgical Approaches in Fulminant Ulcerative Colitis." Global Journal For Research Analysis 3, no. 5 (June 15, 2012): 115–17. http://dx.doi.org/10.15373/22778160/may2014/43.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Tomasik, Mikołaj, Paweł Warzyszak, Róża Małek, Maria Milczek, Wojciech Żołyniak, Izabela Hawranik, Szymon Niski, Ziemowit Żaba, Aleksandra Lisowska, and Mateusz Skrzypek. "Ulcerative colitis – recent and potential methods of treatment - review." Journal of Education, Health and Sport 13, no. 3 (January 17, 2023): 65–73. http://dx.doi.org/10.12775/jehs.2023.13.03.009.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introduction and purpose: Ulcerative colitis (UC, colitis ulcerosa) belongs to a group of inflammatory bowel diseases of unexplained etiology. It is a diffuse nonspecific inflammation of the mucosa of the rectum or rectum and colon, leading to ulceration in more severe cases. Despite a decline in the incidence of ulcerative colitis in developed countries, the prevalence continues to rise due to increasingly predominant benign course of the disease with a low mortality rate. The purpose of this review is to summarize latest directions and discoveries in research of ulcerative colitis. Materials and methods: This review is based on articles published in Pubmed between 2017 and 2022 by searching keywords ulcerative colitis treatment, ulcerative colitis guidelines.State of knowledge: Currently, many independent scientific societies represent a consensus position on the standard management of patients with UC, while recent therapeutic options are constantly emerging due to intensive research. These options require the involvement of multiple medical centers to determine their position in future guidelines.Conclusion: Although ulcerative colitis is a disease that is diagnosed and detected relatively easily, due to its chronic nature, relatively high prevalence in the population and lack of causal treatment options, it is an important direction for further research.
6

Arellano, Nelson Darío, and Larissa Inés Páez. "Colectomy for severe ulcerative colitis." Anales de la Facultad de Ciencias Médicas (Asunción) 54, no. 2 (August 30, 2021): 151–56. http://dx.doi.org/10.18004/anales/2021.054.02.151.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Soni, Dr Aakanksha. "Evaluation of the Factors Associated with Post-Operative Outcome in Patients of Ulcerative Colitis Undergoing Ileal Pouchanal Anastomosis with Comparison of Functional Outcome between Stapler and Hand-Sewn Anastomosis." Journal of Medical Science and clinical Research 12, no. 01 (January 31, 2024): 11–19. http://dx.doi.org/10.18535/jmscr/v12i01.03.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
ntroduction Ulcerative colitis defined as a non-granulomatous idiopathic inflammatory disease which mainly affects the colon and rectum. The disease may arise at any age but most commonly affects the adults between the age group of 30–40 years.1,2. The etiology of the disease is multifactorial, involving genetic predisposition, dysregulated immune responses, epithelial barrier defects and environmental factors. No sex predilection is seen in ulcerative colitis.3,5 The peak age of onset of disease is between 30 to 40 years.4,6 The environmental factors has also been found to play an important role in the etiopathogenesis of ulcerative colitis. Cigarette smoking is one of the major factor associated with ulcerative colitis, non-smokers have a milder disease course and active smokers are less likely to develop ulcerative colitis7 Appendectomy also confers a protective effect against ulcerative colitis, especially in young patients operated for acute appendicitis.8. Classic findings in endoscopy in patients with ulcerative colitis include loss of normal vascular pattern, erythema, erosions, granularity, friability, ulcerations and bleeding9 . The primary aim of medical management is to induce and maintain remission with the long-term goals of improving quality of life and prevent disability. Absolute indications for surgery include uncontrolled hemorrhage, perforation, and colorectal carcinoma or dysplastic lesions not amenable to endoscopic removal.10 Surgery is also indicated in refractory acute severe ulcerative colitis or medically refractory disease. The most commonly performed surgery for ulcerative colitis is restorative proctocolectomy with ileal pouchanal anastomosis (IPAA). An important aspect of the surgery is the use of either sutures or staplers for anastomosis. Two types of ileal pouch-anal anastomosis (IPAA) have been described: a mucosectomy of the rectal stump followed by a hand-sewn ileal pouch-anal anastomosis.11 The alternative technique is to retain the mucosa of the rectal stump and perform a stapled pouch-anal anastomosis.
8

Jaeger, Karine Nava, Maria Eduarda Mintzfels Branco, Ileana Simone de Oliveira Moura, Lorenzo Gabriel de Azevedo Viera, Jhoni Michael de Oliveira Cardoso, Caroline Bezerra Trajano dos Santos, Carlos Galvão Branco Araújo, et al. "Segurança do Vedolizumabe no tratamento da Retocolite Ulcerativa: Uma revisão de literatura." Brazilian Journal of Implantology and Health Sciences 6, no. 1 (January 26, 2024): 1918–26. http://dx.doi.org/10.36557/2674-8169.2024v6n1p1918-1926.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
A colite ulcerativa pertence ao grupo de doenças inflamatórias intestinais, que representam patologias influenciadas por fatores genéticos e ambientais, resultando em um desequilíbrio imunológico seguido de lesões teciduais. Essas provocações ambientais desencadeiam processos inflamatórios restritos à camada mucosa do cólon, em especial no reto, podendo avançar para outras regiões. As principais intervenções terapêuticas são o manejo cirúrgico e o uso de medicamentos, como o Vedolizumabe. Este artigo tem por objetivo realizar uma varredura da literatura médica vigente sobre o tratamento da Retocolite Ulcerativa utilizando o Vedolizumabe. Trata-se de uma revisão integrativa da literatura, utilizando as bases de dados Pubmed e Biblioteca Virtual de Saúde (BVS), por meio do cruzamento dos descritores “vedolizumab”, “therapeutic” e “ulcerative colitis”, com operador booleano “AND”. As buscas resultam em 509 artigos, sendo selecionados os que coincidem com a temática em foco e excluídos o restante pela menor abrangência e fuga do tema. Dentre os critérios de inclusão, foram inseridos artigos em português, inglês e espanhol, em especial dos últimos 5 anos, resultando em 6 artigos. O fármaco Vedolizumabe possui propriedades imunossupressoras específicas ao intestino, demonstrando indicação para o tratamento da colite ulcerativa moderada a grave. Esse medicamento, apresenta ação através da sua ligação à integrina α4β7 expressa em linfócitos T intestinais, inibindo o processo inflamatório e diminuindo a sintomatologia do paciente. Assim, medidas terapêuticas por meio desse fármaco, destinada a pacientes com retocolite ulcerativa, mostra-se segura e eficaz.
9

Proujansky, Roy, Paul T. Fawcett, Kathleen M. Gibney, William R. Treem, and Jeffrey S. Hyams. "Examination of Anti‐Neutrophil Cytoplasmic Antibodies in Childhood Inflammatory Bowel Disease." Journal of Pediatric Gastroenterology and Nutrition 17, no. 2 (August 1993): 193–97. http://dx.doi.org/10.1002/j.1536-4801.1993.tb10946.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
SummaryThe detection of anti‐neutrophil cytoplasmic antibodies (ANCA), in a perinuclear fluorescence pattern, in the serum of adults with inflammatory bowel disease has recently been described to be sensitive and specific for a diagnosis of ulcerative colitis in comparison to Crohn's disease and other colitides. We have examined the sera of 41 children and adolescents with ulcerative colitis, 27 with Crohn's disease, and a control group for the presence of ANCA. Anti‐neutrophil cytoplasmic antibodies were detected in the serum of 27 of 41 patients with ulcerative colitis (66%), five of 27 with Crohn's disease (19%), and in none of our control subjects or patients with functional abdominal pain. Overall, the presence of ANCA was 66% sensitive and 84% specific for a diagnosis of ulcerative colitis when compared to Crohn's disease. There was no relationship between a positive ANCA value and disease activity or other clinical indicators. We conclude that evaluation for the presence of ANCA may be a useful adjunct for the clinical assessment of patients with inflammatory bowel disease. The presence of ANCA in children and adolescents, however, will not definitively distinguish between patients with ulcerative colitis and Crohn's disease.
10

Lakatos, László, and Péter László Lakatos. "Medical therapy of inflammatory bowel diseases: Ulcerative colitis." Orvosi Hetilap 148, no. 25 (June 1, 2007): 1163–70. http://dx.doi.org/10.1556/oh.2007.28063.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
A colitis ulcerosa kezelésében kevesebb a változás, mint a Crohn-betegségben. A betegek nagy többsége ma is a hagyományos gyógyszereket kapja. A kezelést meghatározó legfontosabb tényezők a betegség kiterjedése és súlyossága. Az enyhe és középsúlyos colitis ulcerosa kezelésének a legfontosabb szerei az aminoszalicilátok. Az új 5-aminoszalicilátok terápiás hatékonysága nem jobb, mint a sulfasalaziné, de kevesebb mellékhatásuk miatt előtérbe került az alkalmazásuk. Proctitisben és distalis colitisben a helyileg alkalmazott készítmények hatásosabbak, mint az orális szerek, de a kiterjedt colitis gyógyulását is javítja a kombinált lokális és orális kezelés. A súlyos, akut colitis ulcerosa kezelésében továbbra is meghatározóak a kortikoszteroidok, a nem reagáló esetekben a cyclosporin vagy az infliximab lehet a colectomia alternatívája. Colitis ulcerosában csaknem minden esetben indokolt a fenntartó kezelés. Valamennyi aminoszalicilát alkalmas a remisszió fenntartására. Továbbra sem tisztázott az optimális aminoszalicilát-dózis kérdése. A distalis colitis remisszióban tartásában leghatékonyabbak a lokális szerek, amennyiben a beteg ezt a kezelést elfogadja. Krónikusan aktív, szteroidra rezisztens vagy szteroidfüggő betegségben immunszuppresszív szerektől, elsősorban azathioprintól várhatunk eredményt. Az utóbbi évek felmérései szerint colitis ulcerosában az azathioprin legalább olyan hatékony, mint Crohn-betegségben. A fenntartó kezelésben fontos szempont a kemoprevenció. Mind több adat bizonyítja, hogy az aminoszalicilátok csökkentik a colitis ulcerosában fokozott colorectalis rák kialakulásának kockázatát. A legfontosabb változások a colitis ulcerosa kezelésében az utóbbi években a lokális aminoszalicilátok és az azathioprin előtérbe kerülése, az infliximab alkalmazása súlyos colitisben, valamint a karcinóma-kemoprevenció általánossá válása. Nagyobb figyelmet kell fordítani a beteg együttműködésének a megnyerésére, az előírások betartására.
Більше джерел
Також вас можуть зацікавити розширені добірки на тему "Ulcerative colitise" для конкретних типів джерел:
Статті в журналах Дисертації Книги

Дисертації з теми "Ulcerative colitise":

1

Rivière, Pauline Mayalen. "FMIcroorganisms as Triggers in Acute severe ulcerative Colitis and their influence on medical therapy efficacy : a multi-omics approach, the ITAC project." Electronic Thesis or Diss., Bordeaux, 2023. http://www.theses.fr/2023BORD0474.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
La colite aiguë grave est un phénotype spécifique de poussée de rectocolite hémorragique caractérisé par une inflammation systémique associée à une diarrhée sanglante, associé à un risque de colectomie de 20 % et une mortalité de 1 %. On en sait peu sur la physiopathologie de la colite aiguë grave. Les micro-organismes ont été proposés comme déclencheurs de la colite aiguë grave en raison de la similitude entre ce phénotype et les colites infectieuses, en particulier la présence de l'inflammation systémique. De plus, le microbiote intestinal joue un rôle clé dans la protection contre les agents pathogènes et dans la physiopathologie de la rectocolite hémorragique. Nous avons émis l'hypothèse qu'un microbiote intestinal dysfonctionnel, caractérisé par un appauvrissement de sa diversité et la perte d'espèces bactériennes anti-inflammatoires, permettrait la prolifération d'un pathobionte dans la lumière colique, déclenchant une réponse inflammatoire systémique chez les hôtes dotés d'une immunité muqueuse intestinale permissive, conduisant ainsi à une colite aiguë grave.L'objectif général de notre étude était d'identifier le ou les composants du microbiote et les facteurs liés à l'hôte responsables de la colite aiguë grave. Nous avions trois objectifs spécifiques : (i) comparer le microbiote intestinal des patients atteints de colite aiguë grave à celui des patients présentant une poussée non sévère de rectocolite hémorragique en utilisant le séquençage du gène de l'ARNr 16S sur des échantillons de selles et des biopsies rectales. Les patients atteints de colite aiguë grave présentaient des altérations significatives de leur microbiote intestinal, caractérisées par une réduction de l'alpha-diversité, une présence accrue de Proteobacteria, en particulier de membres du genre Escherichia/Shigella, et une réduction de l'abondance des membres des familles Lachnospiraceae et Ruminococcaceae ; (ii) identifier les sous-types cellulaires et les voies impliquées dans l'inflammation de la 4 muqueuse intestinale chez les patients atteints de colite aiguë grave par rapport aux patients atteints de poussées de rectocolite hémorragique non sévère en utilisant un séquençage de l'ARN sur cellules uniques provenant de biopsies rectales. Dans les cas sévères, les plasmocytes présentaient un profil transcriptomique distinct avec une production accrue d'IgG, et la présence d’une population spécifique de lymphocytes T exprimant l'IL26 était augmentée par rapport aux cas non sévères. Les cellules immunitaires innées présentaient un profil pro-inflammatoire. À la fois, les lymphocytes T et les cellules immunitaires innées indiquaient un environnement muqueux pro-Th17 ; (iii) déterminer les voies de l'hôte qui sous-tendent la poussée inflammatoire systémique en utilisant le séquençage d'ARNm sanguin chez les patients atteints de colite aiguë grave par rapport aux patients atteints de poussées non sévères. Nous n'avons observé aucune distinction claire entre les cas graves et non graves et n'avons identifié aucune voie enrichie en gènes différentiellement exprimés. Cette observation suggère qu'en cas de colite aiguë grave, l'inflammation systémique est moins susceptible d'être orchestrée par des cytokines provenant de cellules circulantes mais plutôt provenant des cellules inflammatoires coliques. Cette étude apporte des informations sur les composants cellulaires et bactériens essentiels impliqués dans la physiopathologie de la colite aiguë grave. Ces résultats ouvrent des perspectives pour la recherche clinique future. Ils indiquent que les efforts pourraient s’orienter vers la modulation du microbiote, des interventions ciblées sur les plasmocytes ou une inhibition nuancée de l'axe Th17/IL-23 pour la gestion des patients atteints de colite aiguë grave
Acute severe ulcerative colitis is a specific ulcerative colitis (UC) flare characterised by systemic inflammation on top of bloody diarrhoea, leading to a 20% risk of colectomy and 1% mortality risk. Little is known about acute severe ulcerative colitis pathophysiology. Microorganisms have been proposed as triggers for acute severe ulcerative colitis because of the similarity, most notably systemic inflammation, between this phenotype and infectious colitis. Moreover, gut microbiota are key players for protection against pathogens and in UC inflammation. We hypothesised that a dysfunctional gut microbiome, characterised by a lack of diversity and the loss of anti-inflammatory bacterial species, would allow the proliferation of a pathobiont in the colonic lumen eliciting a systemic inflammatory response in hosts with permissive gut mucosal immunity leading to an acute severe ulcerative colitis flare. The general objective of my study was to identify the microbiome component(s) and the host factors leading to acute severe ulcerative colitis. We had three specific aims: (i) to compare the gut microbiota of patients with acute severe ulcerative colitis compared to patients with a non-severe ulcerative colitis flare using 16S rRNA gene sequencing of stool samples and rectal biopsies. Patients with acute severeulcerative colitis displayed significant alterations in their gut microbiota, characterised by reduced alpha-diversity, an increased presence of Proteobacteria, particularly members of the Escherichia/Shigella genus, and a reduction in the abundance of Lachnospiraceae and Ruminococcaceae family members; (ii) to identify the cellular subtypes and pathways involved in gut mucosal inflammation in acute severe ulcerative colitis patients compared to non-severe ulcerative colitis patients by single-cell RNA-Seq of rectal biopsies. In severe cases, plasmablasts exhibited a distinct transcriptomic profile with increased IgG production, 2and a specific T cell population expressing IL26 was expanded compared to non-severe cases. Innate immune cells displayed a pro-inflammatory profile. Both T cells and innate immune cells indicated a pro-Th17 mucosal environment; (iii) to determine the host pathways mediating the systemic inflammatory outburst using whole blood RNA-Seq in acute severe ulcerative colitis patients compared to non-severe ulcerative colitis patients. We found no clear distinction between severe and non-severe cases and did not identify any pathways enriched with differentially expressed genes. This observation suggests that in acute severe ulcerative colitis, the systemic inflammation is less likely to be orchestrated by cytokines originating from circulating cells but rather from inflammatory cells located in the colonic mucosa. This multi-omics study contributes valuable insights into the pivotal cellular and bacterial components involved in the pathogenesis of acute severe ulcerative colitis. These findings have the potential to guide future clinical research, directing efforts toward microbiome modulation, targeted interventions on plasmablasts, or nuanced inhibition of the Th17/IL-23 axis
2

Maldaun, Daisy 1944. "Analise qualitativa dos aspectos emocionais e vivenciais de pacientes idosos portadores de retocolite ulcerativa inespecifica em atendimento ambulatorial." [s.n.], 2006. http://repositorio.unicamp.br/jspui/handle/REPOSIP/252522.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Orientadores: Zula Garcia Giglio, Juvenal Ricardo Navarro Goes
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Educação
Made available in DSpace on 2018-08-06T15:30:21Z (GMT). No. of bitstreams: 1 Maldaun_Daisy_M.pdf: 580822 bytes, checksum: f5f1e583f2cc833273662dd98f503183 (MD5) Previous issue date: 2006
Resumo: Desde a Antiguidade, sabe-se, através dos registros da História, que sentimentos e emoções apresentam uma ressonância no corpo. No decorrer dos séculos, o avanço da medicina permitiu o conhecimento da existência de mecanismos através dos quais as emoções podem dar origem ao processo do adoecer. O objetivo deste estudo foi compreender os aspectos emocionais como a ansiedade, o medo e a raiva de pacientes com idade entre 51 e 74 anos portadores de Retocolite Ulcerativa Inespecífica (RCUI) - doença inflamatória intestinal de etiologia desconhecida, bem como viabilizar os resultados desta pesquisa a familiares e profissionais da saúde, numa tentativa de mostrar sua relevância no surgimento e evolução da doença. Como método de pesquisa, optou-se pelo Clínico-Qualitativo. Foram estudados oito (08) casos de pacientes portadores de RCUI, de ambos os sexos, com idades entre 51 e 74 anos. Como procedimento de investigação, foram realizadas entrevistas semidirigidas de questões abertas, levando em consideração a verbalização dos doentes em relação às mudanças ocorridas em suas vidas após o surgimento da doença. Quanto aos resultados, o referencial teórico utilizado para a sua interpretação foi baseado nos conceitos usuais da Psicologia Médica e da Medicina Psicossomática. e da Psicologia Compreensiva Explicativa e Fenomenológica de JASPERS,K. Considerou-se, após a avaliação dos aspectos emocionais desses pacientes através de seus depoimentos, que sua influência é relevante no desencadear e na evolução da RCUI. A psicoterapia, como um instrumento de ajuda e suporte ao tratamento clínico, deve colocar-se a serviço deste Ser doente e em prol da possibilidade de elaboração de uma nova forma de ele vivenciar a doença e seus conflitos, sejam quais forem os recursos de que ele dispõe para manifestá-los
Abstract: Ever since the early Ages, it is common knowledge that feelings and emotions resonate in the body. Throughout the centuries, the advance of medicine has brought to light the knowledge of existing mechanisms through which emotions can give rise to the process of getting sick. The objective of this study was to understand the emotional aspects, such as anxiety, fear and rage of patients aged between 51 and 74 with Unspecified Ulcerative Colitis, an inflammatory intestinal disease of unknown etiology. We also aim to make the results of the present study available to patients¿ family members and health professionals as a means to raise their awareness of the relevance of emotional aspects to the rise and evolution of the illness. The Method chosen to carry out the study was the Qualitative-Clinical Method; eight (08) patients of both sexes were studied. The investigative procedure consisted of semi-direct interviews of open questions; taking into consideration the patients¿ accounts on the changes occurred in their lives before and after the illness manifested itself. The theoretical reference point used for the interpretation of the results was based on the usual concepts of Medical Psychology and Psychosomatic Medicine and of the Comprehensible Explanatory Psychology and Phenomenology of JASPERS, K. Following the evaluation of the emotional aspects these patients mentioned in their testimonials, we concluded that they have great influence on the manifestation of the illness, and that psychotherapy, as an instrument of support for the clinical treatment, should be applied to offer them a new means of understanding the causes of their suffering in the search for a way to deal with the disease and the conflicts it brings along, regardless of which resources they may have available to do so
Mestrado
Gerontologia
Mestre em Gerontologia
3

Luchini, Ana Carolina. "Avaliação dos efeitos da cumarina e da 4-hidroxi-cumarima e de diferentes associações com a sulfassalazina no modelo de colite induzida por ácido trinitrobenzenosulfônico (TNBS) em ratos /." Botucatu, 2009. http://hdl.handle.net/11449/102429.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Orientador: Luiz Claudio Di Stasi
Banca: Célia Akiko Hiruma
Banca: Claudia Helena Pellizzon
Banca: Alessandra Gambero
Banca: Marcelo Aparecido da Silva
Resumo: As cumarinas representam uma importante classe de compostos fenólicos com inúmeras propriedades farmacológicas que incluem inibição da peroxidação lipídica, da geração de ânion superóxido dependente de neutrófilos, da citotoxicidade induzida por hidroperóxido de ácido linoleíco, da atividade de lipooxigenases e ciclooxigenases, além de agirem como agentes imunossupressores e antiinflamatórios. Todas estas propriedades são essenciais para que um produto seja potencialmente ativo para o tratamento das doenças inflamatórias intestinais (DII). A sulfassalazina (primeira opção terapêutica no tratamento das DII) possui vários efeitos colaterais, especialmente quando usada em altas doses ou em períodos longos de tratamento. O objetivo do presente trabalho foi avaliar se cumarina e 4-hidroxi-cumarina possuem efeitos preventivos e/ou curativos no modelo de colite induzida por ácido trinitrobenzenosulfônico (TNBS) em ratos e também se as associações de cumarina ou 4-hidroxi-cumarina com doses menores de sulfassalazina produzem efeitos antiinflamatórios com menor incidência de efeitos colaterais decorrentes da administração da sulfassalazina. Além disso, foram feitos estudos complementares para verificar se tais cumarinas modulam a produção de citocinas próinflamatórias em cultivos celulares in vitro e ex vivo. Este estudo testou a atividade antiinflamatória dos compostos-testes cumarina (2,5 a 50mg/Kg) e 4-hidroxicumarina (5 a 50mg/Kg) e das associações de cumarina com a sulfassalazina (C5+S5; C5+S15 e C5+S25) ou da 4-hidroxi-cumarina com a sulfassalazina (4-OHC25+S5, 4-OHC25+S15 e 4-OHC25+S25) em duas condições experimentais distintas: quando a mucosa colônica está intacta (efeito preventivo); quando a mucosa colônica está afetada por um processo inflamatório intestinal (efeito curativo) assim como preventivo da recidiva do processo inflamatório ... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Coumarins comprise an important class of phenolic compounds with many pharmacological properties that includes inhibition of membrane lipid peroxidation, inhibition on neutrophil-dependent superoxide anion generation, inhibition on the linoleic acid hydroperoxide-induced cytotoxicity, and inhibition on cyclooxygenase and lipoxygenase activities, which could result in antiinflammatory and immunosuppressant effect. Those are some desired features for a candidate compound in the treatment of inflammatory bowel diseases (IBD). On the other hand, the IBD are life persisting diseases with unpredictable episodic reactivations and difficult treatment in severe cases. Sulfasalazine, the first choice drug in the treatment of mild to moderately active IBD cases, presents serious side effects when used in high doses or in long-term treatment. Thus, the aim of this study was to evaluate the effects of coumarin and 4-hydroxy-coumarin in rat experimental intestinal inflammation. Additionally, we evaluated the possibility of coumarins association to sulfasalazine in rat intestinal inflammatory conditions. For this purpose, the antiinflammatory activity of test compounds, coumarin (2.5 to 50mg/kg) and 4-hydroxy-coumarin (5 to 50mg/kg) and associations of coumarin with sulfasalazine (C5 plus S5, C5 plus S15, C5 plus S25) or 4-hydroxy-coumarin with sulfasalazine (4-OHC25 plus S5, 4-OHC25 plus S15 and 4-OHC25 plus S25) were tested in the model of trinitrobenzenesulphonic acid (TNBS) induced rat colitis in two different experimental conditions: when the colonic mucosa is intact (preventive effect), and when a previous inflammatory damage is caused to the colonic mucosa (curative effect), additionally to a reactivation of the inflammatory process (relapse prevention). The colonic damage was evaluated macroscopically, histologically and biochemically. For cell cultures evaluation of cytokine ... (Complete abstract click electronic access below)
Doutor
4

Hartmann, Renata Minuzzo. "O efeito antioxidante da Boswellia serrata no modelo experimental de colite induzida por ácido acético." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2012. http://hdl.handle.net/10183/70400.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introdução: A retocolite ulcerativa indeterminada é uma doença inflamatória que envolve exclusivamente o cólon e o reto, sendo caracterizada por infiltrado leucocitário e úlceras superficiais na mucosa intestinal. A produção e liberação de espécies reativas de oxigênio e nitrogênio parecem ser cruciais na determinação da fisiopatologia da doença, pois resultam em dano oxidativo. A partir dessas informações, a busca por opções terapêuticas com propriedades antioxidantes são importantes e têm sido testadas na colite experimental. Objetivo: Este estudo tem como objetivo avaliar os efeitos do extrato seco da planta Boswellia serrata em modelo experimental de colite induzida por ácido acético sobre os danos teciduais, a pressão anal esfincteriana, o estresse oxidativo, a atividade das enzimas antioxidantes superóxido dismutase (SOD) e glutationa peroxidase (GPx) e atividade da glutationa (GSH), a concentração dos metabólitos do óxido nítrico e expressão da enzima óxido nítrico sintase induzível (iNOS) por imunohistoquímica. Material e métodos: Foram utilizados 25 ratos Wistar machos, com peso médio de 350g, divididos em 5 grupos: Controle (CO); Controle+Boswellia serrata (C+B); Colite (CL); Colite+Boswellia serrata (CL+B) e Boswellia serrata+Colite (B+CL). Os animais foram submetidos à administração intracolônica por enema com solução de ácido acético diluído a 4% e com volume de 4 mL. O tratamento com o extrato aquoso da planta via oral, na dose de 34,2 mg/Kg diluído em 4 mL de solução fisiológica, ocorreu uma vez ao dia durante 48 horas antes e após a indução da colite. Foi realizada a medida de pressão anal esfincteriana dos animais. As análises histológicas do intestino foram através da coloração de Hematoxilina-Eosina e realizada imunohistoquímca com anticorpo iNOS. O homogeneizado do intestino foi utilizado para avaliação da lipoperoxidação (LPO) através das substâncias reativas ao acido tiobarbitúrico (TBARS), avaliação dos metabólitos do óxido nítrico pela técnica de nitritos e nitratos totais, avaliação da atividade das enzimas antioxidantes SOD e GPx e avaliação da GSH. Resultados: Na análise da pressão anal esfincteriana os animais dos grupos CL+B e B+CL apresentaram um aumento significativo em relação ao grupo CL. Nos níveis de LPO e metabólitos do óxido nítrico foi observada uma diminuição significativa nos grupos CL+B e B+CL quando comparados ao grupo CL. A atividade da SOD mostrou um aumento no grupo CL e uma diminuição significativa nos grupos CL+B e B+CL equivalendo à média do grupo CO. A GPx e GSH apresentaram um aumento significativo nos grupos CL+B e B+CL em relação ao grupo CL. Conclusão: Sugerimos que a administração do extrato da planta Boswellia serrata possa ser uma possibilidade de terapia antioxidante na colite ulcerativa.
Introduction: Ulcerative rectocolitis is an inflammatory disease that involves only the colon and rectum, being characterized by leukocyte infiltrate and superficial ulcers in the intestinal mucosa. The production and release of reactive oxygen and nitrogen species appears to be crucial in determining the pathophysiology of the disease, since both result in oxidative damage. Therefore, the search for treatment options with antioxidant properties is important currently and has been tested in experimental colitis. Objective: This study aimed to evaluate the effects of dry extract of Boswellia serrata plant in an experimental model of colitis induced by acetic acid on tissue injury, anal sphincter pressure, oxidative stress, on the activity of antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione (GSH), concentration of nitric oxide metabolites and expression of inducible nitric oxide synthase enzyme (iNOS) by immunohistochemistry. Methods: We used 25 male Wistar rats with an average weight of 350g, divided into 5 groups: control (CO), Control + Boswellia serrata (CO+B); Colitis (CL); Colitis + Boswellia serrata (CL+B) and Boswellia serrata + colitis (B+CL). The animals were submitted to intracolonic administration by enema with acetic acid solution diluted to 4% in a volume of 4 ml. The treatment with aqueous plant extract was performed orally at a dose of 34.2 mg/kg diluted in 4 ml of saline. The administration occurred once daily for 48 hours before and after the induction of colitis. We performed the measurement of anal sphincter pressure animals. Histological analyzes of bowel the after were made staining with hematoxylin-eosin and immunohistochemistry, performed with iNOS antibody. The homogenized intestine was used for evaluation of lipid peroxidation (LPO) through thiobarbituric acid reactive substances (TBARS), assessment of nitric oxide metabolites by the technique of total nitrites and nitrates and evaluation of the antioxidant enzymes SOD, GPx and GSH. Results: The analysis of anal sphincter pressure of the animals in groups CL+B and B+CL showed a significant increase when compared to the CL group. LPO and nitric oxide metabolites levels demonstrated significant decrease in groups CL+B and B+CL when compared to CL. SOD activity showed an increase in CL group and a significant decrease in groups CL+B and B+CL, remainig to the average of the CO group. The GPx and GSH showed a significant increase in groups CL+B and B+CL group when compared to CL group. Conclusion: We suggest that the administration of Boswellia serrata plant extract may be a possibility of antioxidant therapy in ulcerative colitis.
5

Almeida, Maristela Gomes de. ""Estudo da microbiota intestinal em doentes com retocolite ulcerativa antes e após retocolectomia com anastomose de bolsa ileal ao canal anal"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5154/tde-19102005-160653/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Este estudo tem como objetivo, descrever a microbiota intestinal de pacientes com retocolite ulcerativa grave, em tratamento clínico, antes e após retocolectomia com anastomose de bolsa ileal ao canal anal. Comparou-se a flora bacteriana do íleo terminal e do reto no pré-operatório com a flora encontrada na bolsa ileal após dois e oito meses do fechamento da ileostomia e com a flora do íleo terminal e do reto de um grupo controle. Observou-se que a Veillonella sp foi a bactéria mais freqüentemente encontrada em todos os grupos. Não houve diferenças significativas entre a flora intestinal do grupo controle e dos pacientes com retocolite ulcerativa
The aim of this study is to describe the intestinal microbiota of patients with severe ulcerative colitis, under clinical treatment, before and after proctocolectomy and ileal pouch-anal anastomosis. Intestinal flora of distal ileum and rectum before surgery was compared with the flora found in ileal pouch after two and eight months after ileostomy closure and with the flora of distal ileum and rectum of controls. Veillonella sp was the most frequent microorganism found in all groups. There were no significant differences between the intestinal microbiota found in controls and in patients with ulcerative colitis
6

Thomas, Gareth Andrew Osbert. "Nicotine therapy for ulcerative colitis." Thesis, Queen Mary, University of London, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309526.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Pullan, Rupert Derek. "Colonic mucus and ulcerative colitis." Thesis, University of Oxford, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.358954.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Burke, Denis Anthony. "Ulcerative colitis and Escherichia coli." Thesis, University of Newcastle Upon Tyne, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309075.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Finnie, Ian A. "Mucosal metabolism and ulcerative colitis." Thesis, University of Aberdeen, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342167.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The relationship between human colonic mucosal metabolism and mucin synthesis was explored, with particular reference to ulcerative colitis (UC) and pouchitis. A hypothesis was proposed, that UC and pouchitis result from impaired metabolism of butyrate, and that the outcome of this metabolic event was reduced mucosal protection via effects on mucin synthesis. The study aims were to assess mucosal metabolism in the ileum and colon in controls and in UC, and to assess the effects of agents that are effective therapy for UC on metabolism as measured by mucin synthesis. In histologically normal colonoscopic mucosal biopsies cultured in vitro, the rate of metabolism of butyrate was similar in the ascending (AC) and descending colon (DC). There was a higher rate of metabolism of glutamine in the ascending colon, in agreement with previous work which stressed the relatively greater dependence of the distal colon on butyrate as an energy source. The terminal ileum (TI), in controls had a surprisingly high rate of metabolism of butyrate, significantly higher than the AC, glutamine metabolism in controls was also greater than in the AC. In ulcerative colitis (UC) the most striking change in epithelial metabolism was an increase in the rate of glutamine metabolism in the descending colon. The rates of butyrate metabolism in UC were similar to those in controls, the ratio of butyrate:glutamine metabolism was non-significantly lower in the descending colon in UC as a result of the increased rate of glutamine metabolism. Rates of metabolism in the terminal ileum were similar in UC and controls. Butyrate, at concentrations that are likely to be physiologically and pharmacologically relevant, significantly increased mucin synthesis in colonic mucosal explants from histologically normal and diseased (UC) tissue. Glucocorticoids and nicotine similarly increased colonic mucin synthesis, whereas mineralocorticoids were without effect.
10

Hearing, Stephen David. "Steroid resistance in ulcerative colitis." Thesis, University of Bristol, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324259.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Ulcerative colitise":

1

Poggioli, Gilberto, ed. Ulcerative Colitis. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

R, Gibson P., ed. Ulcerative colitis. London: Baillière Tindall, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

National Digestive Diseases Information Clearinghouse (U.S.). Ulcerative colitis. Bethesda, Md: U.S. Dept. of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Digestive Diseases Information Clearinghouse, 2006.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

A, Ó'Moráin Colm, ed. Ulcerative colitis. Boca Raton: CRC Press, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lichtenstein, Gary R. Ulcerative Colitis. Boca Raton: CRC Press, 2024. http://dx.doi.org/10.1201/9781003526827.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

1939-, Jagelman David, ed. Mucosal ulcerative colitis. Mount Kisco, N.Y: Futura Pub. Co., 1986.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Saibil, Fredric G. Crohn's disease & ulcerative colitis. Toronto: Key Porter Books, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Saibil, Fredric G. Crohn's disease & ulcerative colitis. 2nd ed. Toronto: Key Porter Books, 2003.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Saibil, Fredric G. Crohn's disease & ulcerative colitis. Willowdale, Ont: Firefly Books, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

P, Kelly Michael. Colitis. London: Taylor & Francis Group Plc, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Ulcerative colitise":

1

Poggioli, Gilberto, Marco Salice, Nicola Renzi, and Massimo Campieri. "History of Ulcerative Colitis." In Ulcerative Colitis, 1–16. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Poggioli, Gilberto, and Matteo Rottoli. "Surgical Treatment of Ulcerative Colitis: Laparoscopy and New Minimally Invasive Techniques." In Ulcerative Colitis, 139–53. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_10.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Poggioli, Gilberto, Lorenzo Gentilini, Maurizio Coscia, and Federica Ugolini. "Results and Quality of Life after Surgical Treatment of Ulcerative Colitis." In Ulcerative Colitis, 155–71. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_11.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Poggioli, Gilberto, Lorenzo Gentilini, Maurizio Coscia, and Federica Ugolini. "Long-term Complications after Surgical Treatment of Ulcerative Colitis." In Ulcerative Colitis, 173–94. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Poggioli, Gilberto, Laura Vittori, and Silvio Laureti. "Management and Treatment of Fistulas after Surgical Treatment of Ulcerative Colitis." In Ulcerative Colitis, 195–210. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Poggioli, Gilberto, and Nicola Renzi. "Presentation and Natural Course of Ulcerative Colitis." In Ulcerative Colitis, 17–28. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Serra, Carla, Chiara Praticò, and Alberta Cappelli. "Diagnosis of Ulcerative Colitis: the Role of Imaging Techniques." In Ulcerative Colitis, 29–44. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Poggioli, Gilberto, Massimo P. Di Simone, and Laura Vittori. "Diagnosis of Ulcerative Colitis: the Role of Endoscopy." In Ulcerative Colitis, 45–60. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

D’Errico, Antonietta, and Deborah Malvi. "Diagnosis of Ulcerative Colitis: Morphology and Histopathological Characteristics." In Ulcerative Colitis, 61–92. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Rizzello, Fernando, Marco Salice, Carlo Calabrese, Marta Mazza, Andrea Calafiore, Lucia Calandrini, Hana Privitera Hrustemovic, Massimo Campieri, and Paolo Gionchetti. "Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?" In Ulcerative Colitis, 93–104. Milano: Springer Milan, 2019. http://dx.doi.org/10.1007/978-88-470-3977-3_6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Ulcerative colitise":

1

Wiziack, Matheus da Silva, VITOR ANDRADE, PEDRO RAFAEL MACEDO, ANA CAROLINE RIBEIRO LIMA BORGES, and LARISSA SOARES DE ANDRADE. "FATORES IMUNOLÓGICOS DO EFEITO PROTETIVO DO TABACO NA COLITE ULCERATIVA." In II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/5968.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introdução: A colite ulcerativa (CU) é uma doença inflamatória intestinal (DII) de causa etiológica desconhecida. Há um tempo tem sido destacada na literatura pelo fato de ter o tabagismo como um fator protetivo no desenvolvimento da sua patogênese. No entanto, os mecanismos imunológicos desse efeito ainda são pouco esclarecidos. Objetivos: Descrever os mecanismos imunológicos do efeito protetivo do tabaco na progressão da colite ulcerativa. Metodologia: Trata-se de uma revisão sistemática, na qual foram selecionados artigos científicos publicados no PubMed, entre os anos de 2001 a 2022, a partir das palavras chaves “immunology”, “tobacco” e “colitis”, unidas pelo operador booleano \"AND\", obtendo-se 20 artigos. Posteriormente, selecionaram-se os artigos que respondessem a seguinte pergunta norteadora “Como o tabaco promove efeito protetivo na colite ulcerativa?”, totalizando 8 artigos. Resultados: Avaliou-se que, para a promoção desse efeito protetivo na CU, há uma interação multifatorial entre a nicotina e o sistema imunológico. Estudos relatam que a nicotina atua polarizando os macrófagos para a forma alternativa (M2) através da ativação do α7nAChR (receptor alfa 7- nicotínico presente na superfície de monócitos e macrófagos). Com isso, esse evento promove uma superexpressão das citocinas anti-inflamatórias (IL-4, IL-10, IL-13 e TGF-β) e uma redução das citocinas pró-inflamatórias (iNOS, IL-1, IL-2, IL-6, IL-17, TNF-α). Além disso, também foi relatado que o tabaco é responsável por amenizar o efeito da disbiose gerada pela CU. Ademais, outro fator notado foi a capacidade da nicotina em elevar os níveis do miR-124-IL6R (microRNA), exercendo uma resposta anti-inflamatória, que demonstra a influência epigenética nesse processo protetivo. Conclusão: Em síntese, entre os vários componentes do tabaco, a nicotina é o agente mais ativo e de maior participação nos mecanismos imunológicos que geram proteção contra os efeitos prejudiciais da CU. Dentre esses mecanismos, destacaram o aumento das citocinas anti-inflamatórias e diminuição das citocinas pró-inflamatórias. Outrossim, apesar desse caráter benéfico do tabaco na proteção contra a CU, o tabagismo apresenta maiores efeitos deletérios em várias outras doenças, dessa forma, ainda são necessários mais estudos acerca do uso desses componentes como forma terapêutica.
2

Jodeleit, H., O. Al-amodi, J. Caesar, G. Schütze, L. Holdt, M. Siebeck, R. Gropp, and F. Beigel. "Targeting Ulcerative Colitis with Ritonavir." In 46. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern e.V. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1648609.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Irandost, M., B. Varda, and A. I. Saeed. "Pulmonary Manifestations of Ulcerative Colitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1384.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Aleskerov, F. "Atypical Presentation of Ulcerative Colitis." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3577.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Santos, Daniel Rocha, and Cintya Lopes Caravella Ribeiro. "ASSOCIAÇÃO DE CORTICÓIDES E BIOLÓGICOS NO TRATAMENTO DA RETOCOLITE ULCERATIVA – UMA REVISÃO SISTEMÁTICA." In I Congresso Brasileiro de Saúde Pública On-line: Uma abordagem Multiprofissional. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2871.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introdução: A doença Inflamatória Intestinal (DII) é caracterizada como inflamação crônica da mucosa intestinal e pode ser limitada à zona intestinal ou abranger outros órgãos subjacentes. Compreende basicamente dois tipos de patologias: a Retocolite Ulcerosa ou Retocolite Ulcerativa (RCU) e a Doença de Crohn (DC). A RCU envolve um processo de doença contínuo, afetando o reto e progredindo de forma proximal envolvendo comprimentos variáveis do cólon; já a DC envolve, tipicamente, o intestino delgado e o intestino grosso de forma segmentar, com áreas entrepostas, ou seja, é caracterizado por possuir segmentos saudáveis que separam os segmentos inflamados. Objetivos: Estudar o uso de medicamentos corticóides e biológicos associados no tratamento da RCU. Material e métodos: Revisão bibliográfica descritiva, articulada com as literaturas relacionadas ao tema, realizada no primeiro semestre de 2021, entre os meses de janeiro e março. Foi realizada na base de dados Medline, usando-se os descritores “colite ulcerativa, tratamento e corticoesteróides”, delimitando somente em humanos adultos, e artigos publicados nos últimos 10 anos. Foram incluídos artigos com referência à colite ulcerativa e corticoterapia com biológicos associados. Resultados: Por meio de ensaios clínicos, estudos multicêntricos, randomizados e de diversas regiões, este estudo de revisão contemplou as principais referências para essa abordagem; incluindo a associação de indução de adalimumab e/ou golimumab com a terapia de manutenção em pacientes com colite ulcerativa. Conclusão: O cenário clínico real demonstra uma eficácia favorável da indução de adalimumab e terapia de manutenção em pacientes com colite ulcerativa. O tratamento com golimumab subcutâneo induz a resposta clínica, remissão e cicatrização da mucosa, e aumenta a qualidade de vida em porcentagens maiores de pacientes com RCU ativa.
6

Gada, K., P. S. Masuta, and D. N. Manta. "Atypical Pulmonary Manifestations of Ulcerative Colitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1387.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Bramantya, Rendy Revandana, Iswan Abbas Nusi, Poernomo Boedi Setiawan, Herry Purbayu, Titong Sugihartono, Ummi Maimunah, Ulfa Kholili, et al. "Diagnosis and Management of Ulcerative Colitis." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007339804050412.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Sahu, N., A. K. Rahman, C. Simone, M. DiRico, E. B. Ernst, and N. Fitzpatrick. "The Airway of Refractory Ulcerative Colitis." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1440.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kacmaz, Rukiye Nur, and Bulent Yilmaz. "Detection of Ulcerative Colitis From Colonoscopy Images." In 2018 Medical Technologies National Congress (TIPTEKNO). IEEE, 2018. http://dx.doi.org/10.1109/tiptekno.2018.8596841.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hammami, A., A. Hassine, F. Zinelabidine, Ameur W. Ben, W. Dahmani, N. Elleuch, A. Braham, et al. "Assessment of the Severity of Endoscopic Lesions in Ulcerative Colitis: Endoscopist’s Evaluation Versus Ulcerative Colitis Endoscopic Index Score." In ESGE Days 2021. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1724754.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Ulcerative colitise":

1

Tang, Li-li, Yue-dong Liu, Hong-wu Tao, Wen-zhe Feng, Yu-ping Shu, and Fan-yan Meng. The efficacy and safety of ulcerative colitis treatment based on the theory of the " lung–gut axis ": a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0014.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Review question / Objective: The purpose of this study was to investigate the difference between the curative effect of traditional Chinese medicine or integrated traditional Chinese and Western medicine on ulcerative colitis under the guidance of lung-intestine axis theory and that of Western medicine alone. The selected research method was to search relevant randomized controlled trial in Chinese and English medical databases. The Cochrane bias risk assessment tool was used to analyze the quality of RCT studies, and RevMan 5.3 was used for efficacy evaluation and meta-analysis. Condition being studied: Ulcerative colitis (UC) is a nonspecific intestinal inflammatory disease that often involves the rectum and colon submucosa. It is characterized by abdominal pain, diarrhea and purulent bloody stool. There is no specific therapy for ulcerative colitis at present. This study investigates the curative effect of traditional Chinese medicine or integrated traditional Chinese and Western medicine therapy on UC under the guidance of lung-intestine axis theory and provides a theoretical basis for the clinical treatment of UC.
2

Chengyulin, Wang, Nie Yingjun, and Wu Qiaofeng. Acupucture for Ulcerative Colitis: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0075.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Yang, Dan, Lijiao Yan, Qiulu Mai, Hailing Guo, and Yufang Hao. Navel therapy for Ulcerative Colitis in adults: a systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2020. http://dx.doi.org/10.37766/inplasy2020.12.0146.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Huang, Chih-Wen, Hsu-Heng Yen, and Yang-Yuan Chen. Network Meta-Analysis of Rescue Treatments for Steroid-Refractory Acute Severe Ulcerative Colitis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2024. http://dx.doi.org/10.37766/inplasy2024.3.0113.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Guo, Xinyi, Changxing Liu, and Yahui Huang. Efficacy and safety of vitamin D adjuvant therapy for ulcerative colitis: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0044.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Zhang, Yitao, Tongxin Liu, Chunxiao Yan, Ling Li, Jiaqi Zhang, and Liangrong Zhou. The Acupuncture-related Therapies for Ulcerative Colitis: A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0102.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

zhao, tian, shi qin, and lu fu. Efficacy and safety of Janus kinase inhibitors for Ulcerative colitis：A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0096.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Liu, Chenyu, Xin Liu, Haitao Shi, Fenrong Chen, Linlang Sun, Xin Gao, and Yan Wang. The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2023. http://dx.doi.org/10.37766/inplasy2023.8.0081.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Xiong, PeiYu, Yuhang Ren, Chun Zhong, Peixu Zhang, Xu Chen, Xinglong Chen, and Bo Jia. Treatment of Ulcerative colitis with Chinese herbal medicine enema: a protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0091.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Taxonera, Carlos, and David Olivares. Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: A systematic review and meta-analysis. Peeref, June 2023. http://dx.doi.org/10.54985/peeref.2306p5797828.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

До бібліографії